Combined Targeted Therapy and Immunotherapy in Metastatic Melanoma

Metastatic melanoma treatment has been transformed by the integration of targeted kinase inhibitors and immune checkpoint blockade. Targeted agents, notably BRAF and MEK inhibitors, elicit rapid tumour regression in patients harbouring activating mutations but are limited by the near-inevitable emergence of resistance. Immune checkpoint inhibitors, such as those directed against PD-1 and CTLA-4, produce more durable responses by reactivating antitumour T-cell activity, yet yield modest initial response rates. Combining these modalities seeks to capitalise on their complementary strengths: targeted therapy can enhance tumour antigen expression and T-cell infiltration, while immunotherapy can sustain durable control and prevent early relapse. Preclinical models and early-phase clinical trials have explored concurrent and sequential regimens, addressing optimal dosing, scheduling and management of overlapping toxicities. Recent advances have also emphasised the role of the tumour microenvironment and minimal residual disease in driving resistance, underscoring the need for predictive biomarkers and novel agents to target persistent cell populations.

Research from Nature Portfolio

Recent studies have uncovered a melanoma-intrinsic mechanism of immune evasion mediated by the chromatin remodeller Mi-2β. Loss of Mi-2β activity or pharmacological inhibition with a novel small-molecule blocker diminishes EZH2-mediated H3K27 trimethylation, restoring accessibility and transcription of interferon-stimulated genes. In preclinical melanoma models refractory to checkpoint blockade, this intervention re-sensitises tumours to anti-PD-1 therapy, resulting in enhanced T-cell infiltration and tumour regression. These findings point to Mi-2β as a promising target for overcoming primary resistance to immunotherapy in metastatic melanoma.

Combined Targeted Therapy and Immunotherapy in Metastatic Melanoma publication trend

The graph below shows the total number of articles in combined targeted therapy and immunotherapy in metastatic melanoma across all publications each year (not limited to Nature Index journals).

Technical terms

BRAF inhibitor: A small molecule that selectively inhibits mutant BRAF kinase, interrupting the MAPK signalling pathway driving melanoma cell proliferation.

MEK inhibitor: A compound targeting MEK1/2 kinases downstream of BRAF, further suppressing oncogenic MAPK signalling.

Immune checkpoint inhibitor: An antibody that blocks regulatory receptors such as PD-1 or CTLA-4 on T cells, thereby restoring antitumour immune responses.

Tumour microenvironment: The complex milieu of stromal, vascular and immune cells, extracellular matrix and signalling molecules surrounding tumour cells.

Minimal residual disease (MRD): The small population of tumour cells that survive initial therapy and can seed disease recurrence.

References

1. Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation. Nature Communications (2024).
2. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?. Cancer and Metastasis Reviews (2023).
3. The therapeutic potential of targeting minimal residual disease in melanoma. Clinical and Translational Medicine (2023).
4. BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. Cancers (2020).